Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
16. Dezember 2024 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
CBIH Files Petition to Include Alexis Bortell as Witness in DEA Rescheduling Hearing
16. Dezember 2024 08:00 ET
|
CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
CBIH has formally filed a petition to have Ms. Alexis Bortell serve as a witness in the upcoming DEA hearing on marijuana rescheduling.
Crossject annonce le succes d’une augmentation de capital reservee à une catégorie d’investisseurs et d’une emission de bons de souscription d’actions pour un montant total de 7,2 millions d’euros
11. Dezember 2024 02:39 ET
|
CROSSJECT
Crossject modifie les termes et conditions des obligations convertibles en actions nouvelles ou remboursables souscrites par Heights Capital Management, Inc. (« Heights ») Dijon, FRANCE, 11 Décembre...
Crossject announces the pricing of its reserved capital increase and warrants issuance for an aggregate amount of EUR 7.2M
11. Dezember 2024 02:39 ET
|
CROSSJECT
Crossject to amend the Heights Capital Management, Inc. (“Heights”) bonds convertible in new shares or repayable Dijon, FRANCE, December 11, 2024 – 8 a.m. (CET) – Crossject (ISIN: FR0011716265;...
A Letter from the Desk of CBIH
09. Dezember 2024 08:00 ET
|
CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
Cannabis Bioscience International Holdings CEO Dante Picazo Addresses Cannabis Reclassification and DEA Hearings
Crossject et le Département américain de la Défense relancent leur coopération en matière de recherche sur les auto-injecteurs sans aiguille en reconduisant leur accord de coopération en R&D
09. Dezember 2024 01:30 ET
|
CROSSJECT
Dijon, France, le 9 décembre 2024, 07:30 CET – Crossject (ISIN : FR0011716265 ; Euronext : ALCJ), une société pharmaceutique spécialisée qui développe l’auto-injecteur sans aiguille primé ZENEO® pour...
Crossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development Agreement
09. Dezember 2024 01:30 ET
|
CROSSJECT
Dijon, France, December 09, 2024, 07:30 CET – Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing the award-winning needle-free ZENEO® autoinjector to deliver...
Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-Resistant Epilepsy Announced at 2024 Annual Meeting of the American Epilepsy Society
06. Dezember 2024 12:00 ET
|
Neurona Therapeutics
Neurona Therapeutics Presents Positive Clinical Update:
New Data from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy Announced at 2024 Annual Meet
Neurology Clinical Trials Market Size Is Expected To Reach a Revenue Of USD 9,231.1 Mn By 2033, at 5.8% CAGR: Dimension Market Research
25. November 2024 09:26 ET
|
Dimension Market Research
New York, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Market Overview The Global Neurology Clinical Trials Market size is expected to reach USD 5,549.3 million by 2024 and it is further anticipated to reach...
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List
25. November 2024 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), today announced it ranked number 452 on the Deloitte Technology Fast...